Patents by Inventor Yoshiaki Isobe
Yoshiaki Isobe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911466Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.Type: GrantFiled: January 25, 2022Date of Patent: February 27, 2024Assignee: Sumitomo Pharma Co., Ltd.Inventors: Hidenori Kimura, Hitoshi Ban, Yoshiaki Isobe, Hitoshi Watanabe
-
Patent number: 11899799Abstract: A system performs an application update process based on security management information that is information including meta information for each of a plurality of security services. The application update process is a process for adding one or more security services including a security service that reduces the security risk of an application having a plurality of distributed microservices having a graph structure relationship to the application.Type: GrantFiled: September 23, 2020Date of Patent: February 13, 2024Assignee: HITACHI, LTD.Inventors: Jens Doenhoff, Nodoka Mimura, Yoshiaki Isobe
-
Publication number: 20230265061Abstract: The present invention relates to a compound of formula (1) wherein Q1 is halogen atom, Q2 is hydrogen atom, etc., X, Y, and Z are nitrogen atom or oxygen atom, and R1 has a given structure, or a pharmaceutically acceptable salt thereof, and a medicament comprising the compound for treating and/or preventing a disease such as epilepsy.Type: ApplicationFiled: March 16, 2021Publication date: August 24, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Yoshiaki ISOBE, Tomoyuki TANAKA, Hirotaka MIYACHI
-
Patent number: 11731960Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.Type: GrantFiled: July 22, 2022Date of Patent: August 22, 2023Assignee: SUMITOMO PHARMA CO., LTD.Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
-
Patent number: 11718592Abstract: The present invention relates to a compound of formula (1) wherein Q1 is halogen atom, Q2 is hydrogen atom, etc., X, Y, and Z are nitrogen atom or oxygen atom, and R1 has a given structure, or a pharmaceutically acceptable salt thereof, and a medicament comprising the compound for treating and/or preventing a disease such as epilepsy.Type: GrantFiled: September 16, 2022Date of Patent: August 8, 2023Assignee: Sumitomo Pharma Co., Ltd.Inventors: Yoshiaki Isobe, Tomoyuki Tanaka, Hirotaka Miyachi
-
Publication number: 20230202991Abstract: The present invention relates to a medicament for treating various nervous system diseases or psychiatric diseases, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein R1 is hydrogen, etc., R2 is halogen, etc., R3, R4, R5, and R6 are hydrogen, etc.Type: ApplicationFiled: July 6, 2021Publication date: June 29, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Tomoyuki TANAKA, Yoshiaki ISOBE, Hiroyuki KITANO, Hiroaki TANAKA, Shun NARAI
-
Publication number: 20230092498Abstract: The present invention relates to a compound of formula (1) wherein Q1 is halogen atom, Q2 is hydrogen atom, etc., X, Y, and Z are nitrogen atom or oxygen atom, and R1 has a given structure, or a pharmaceutically acceptable salt thereof, and a medicament comprising the compound for treating and/or preventing a disease such as epilepsy.Type: ApplicationFiled: September 16, 2022Publication date: March 23, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Yoshiaki ISOBE, Tomoyuki TANAKA, Hirotaka MIYACHI
-
Patent number: 11535599Abstract: The present invention relates to a medicament for treating various nervous system diseases or psychiatric diseases, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein R1 is hydrogen, etc., R2 is halogen, etc., R3, R4, R5, and R6 are hydrogen, etc.Type: GrantFiled: March 22, 2022Date of Patent: December 27, 2022Assignee: Sumitomo Pharma Co., Ltd.Inventors: Tomoyuki Tanaka, Yoshiaki Isobe, Hiroyuki Kitano, Hiroaki Tanaka, Shun Narai
-
Publication number: 20220380353Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X=Y-Z, X-Y=Z, or X-Y-Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.Type: ApplicationFiled: July 22, 2022Publication date: December 1, 2022Applicant: SUMITOMO PHARMA CO., LTD.Inventors: Hitoshi WATANABE, Yoshiaki ISOBE, Hidenori KIMURA, Yuji FUJIWARA
-
Publication number: 20220289694Abstract: The present invention relates to a medicament for treating various nervous system diseases or psychiatric diseases, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein R1 is hydrogen, etc., R2 is halogen, etc., R3, R4, R5, and R6 are hydrogen, etc.Type: ApplicationFiled: March 22, 2022Publication date: September 15, 2022Applicant: Sumitomo Pharma Co., Ltd.Inventors: Tomoyuki TANAKA, Yoshiaki ISOBE, Hiroyuki KITANO, Hiroaki TANAKA, Shun NARAI
-
Patent number: 11440905Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.Type: GrantFiled: October 26, 2020Date of Patent: September 13, 2022Assignee: SUMITOMO PHARMA CO., LTD.Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
-
Patent number: 11418534Abstract: A threat analysis system includes a storage unit that stores first information in which a device configuring a threat analysis target system and a vulnerability included in the device are associated with each other, and second information in which the device and a threat from a viewpoint of a business operator assumed in the threat analysis target system are associated with each other; a threat analysis processing unit that associates the vulnerability included in the device and a threat in the threat analysis target system with each other on a basis of the first information and the second information stored in the storage unit; and a threat-analysis result output unit that outputs a relationship between the vulnerability and the threat associated by the threat analysis processing unit.Type: GrantFiled: February 22, 2019Date of Patent: August 16, 2022Assignee: HITACHI, LTD.Inventors: Akihiro Sugimoto, Yoshiaki Isobe
-
Publication number: 20220226468Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.Type: ApplicationFiled: January 25, 2022Publication date: July 21, 2022Inventors: Hidenori Kimura, Hitoshi Ban, Yoshiaki Isobe, Hitoshi Watanabe
-
Patent number: 11266738Abstract: The present invention provides a compound of the formula (2): wherein X, R1, R2, R3, R4, R5, R6, R8, Y1, Y2, and L are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.Type: GrantFiled: March 18, 2020Date of Patent: March 8, 2022Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hidenori Kimura, Hitoshi Ban, Yoshiaki Isobe, Hitoshi Watanabe
-
Publication number: 20210363810Abstract: Disclosed is a vehicular opening/closing body control device including: a positional information acquisition; a storage part; and a motor control part. The motor control part includes: a drive start part that operates the motor based on the positional information so that the opening/closing body in a stopped state is moved; and a drive part that performs feedback control of the motor based on the positional information and the target value so that the movement speed of the opening/closing body which has been started to move by the drive start part reaches the target value. The drive start part generates a first output in the motor when the opening/closing body is at a first position, and generates a second output smaller that the first output in the motor when the opening/closing body is at a second position closer to a fully closed position than the first position.Type: ApplicationFiled: April 12, 2019Publication date: November 25, 2021Applicant: MITSUBA CorporationInventor: Yoshiaki ISOBE
-
Publication number: 20210198242Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.Type: ApplicationFiled: October 26, 2020Publication date: July 1, 2021Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
-
Publication number: 20210173938Abstract: A system performs an application update process based on security management information that is information including meta information for each of a plurality of security services. The application update process is a process for adding one or more security services including a security service that reduces the security risk of an application having a plurality of distributed microservices having a graph structure relationship to the application.Type: ApplicationFiled: September 23, 2020Publication date: June 10, 2021Inventors: Jens DOENHOFF, Nodoka MIMURA, Yoshiaki ISOBE
-
Publication number: 20210029153Abstract: A threat analysis system includes a storage unit that stores first information in which a device configuring a threat analysis target system and a vulnerability included in the device are associated with each other, and second information in which the device and a threat from a viewpoint of a business operator assumed in the threat analysis target system are associated with each other; a threat analysis processing unit that associates the vulnerability included in the device and a threat in the threat analysis target system with each other on a basis of the first information and the second information stored in the storage unit; and a threat-analysis result output unit that outputs a relationship between the vulnerability and the threat associated by the threat analysis processing unit.Type: ApplicationFiled: February 22, 2019Publication date: January 28, 2021Inventors: Akihiro SUGIMOTO, Yoshiaki ISOBE
-
Publication number: 20210008197Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.Type: ApplicationFiled: March 18, 2020Publication date: January 14, 2021Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hidenori Kimura, Hitoshi Ban, Yoshiaki Isobe, Hitoshi Watanabe
-
Patent number: 10870642Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.Type: GrantFiled: April 24, 2019Date of Patent: December 22, 2020Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara